Syn-Ake

Dosing from the Literature

Published for wrinkles: the maker's 1–4% use level in creams. Not published: a peer-reviewed trial at any strength.

Syn-Ake is a topical cosmetic ingredient. There is no parenteral, oral, or injectable dosing protocol — the molecule has been developed and registered exclusively as a leave-on cosmetic ingredient. The figures below are the manufacturer-recommended use levels and consensus formulator practice.

The Syn-Ake supplied solution typically contains the active peptide at ~0.05–0.1%, so a 4% formula use level corresponds to roughly 20–40 ppm of pure peptide in the finished cosmetic. This is many orders of magnitude below pharmacologically active systemic concentrations of native waglerin-1 in animal-model nerve-muscle preparations, and reinforces why even at the upper-end of the recommended cosmetic use range, the expected effect is modest.

What It Is

Syn-Ake is the trade name of the synthetic peptide ingredient with the INCI designation dipeptide (a chain of 2 amino acids) diaminobutyroyl benzylamide diacetate (CAS 823202-99-9). It was developed in the early 2000s by the Swiss specialty-actives house Pentapharm in Basel — a company subsequently absorbed into DSM Nutritional Products and now part of dsm-firmenich's personal-care actives portfolio. It is supplied to formulators as a water-soluble white powder typically diluted to 0.05–0.1% active in a glycerin / water carrier ("Syn-Ake solution"), with the on-label recommended use level in finished cosmetic products of 1–4% of the diluted Syn-Ake solution (corresponding to a much smaller fraction of pure peptide on a weight/weight basis).

The molecule is a small dipeptide-derivative: a diaminobutyric-acid (Dab) residue coupled to a phenylalanine residue and N-terminally functionalized as a benzylamide, supplied as the diacetate salt. Functionally, it was designed by Pentapharm chemists to recapitulate the bioactive C-terminal region of waglerin-1, a 22-amino-acid neurotoxic peptide isolated in the early 1990s from the venom of the temple pit viper Tropidolaemus wagleri (formerly Trimeresurus wagleri), an arboreal Crotalinae viperid endemic to Malaysia, Indonesia, southern Thailand, and the Philippines. The native peptide is one of the most pharmacologically distinctive components of snake venom because it is one of the only known viperid neurotoxins that selectively antagonizes the muscle-type (α1-containing) nicotinic (a type of acetylcholine receptor on muscle and nerve cells) acetylcholine receptor — most snake nAChR-targeting α-neurotoxins come from the elapid family (cobras, kraits, mambas, sea snakes), not vipers.

The Pentapharm strategy was straightforward: shrink waglerin-1's 22-residue, disulfide-stabilized peptide to a much smaller synthetic dipeptide-derivative that retains a portion of the C-terminal pharmacophore, with the goal of producing a cosmetic ingredient that could be cost-effectively manufactured at industrial scale, would be stable in oil-in-water emulsions and aqueous serums, and could plausibly engage the same postsynaptic nAChR target after topical application. The resulting molecule is registered with the Personal Care Products Council INCI dictionary, listed in the European Cosmetic Ingredients Database (CosIng) without restriction, and is permitted as a leave-on cosmetic ingredient in essentially every regulated cosmetic market globally.

Marketing positioning has, from launch, leaned heavily on the "topical Botox alternative" framing. Trade-press promotional copy and finished-brand marketing routinely use language like "Botox-like effect without injections," "muscle-relaxing peptide," and "snake-venom-inspired anti-wrinkle technology." This positioning sits alongside an entire class of similar cosmetic actives — Argireline (acetyl hexapeptide-8), Leuphasyl (pentapeptide-18), Vialox (pentapeptide-3), and SNAP-8 (acetyl octapeptide-3) — all of which target some component of the neuromuscular junction with the explicit marketing comparison to injectable botulinum toxin (BoNT). The honest scientific reality across this entire class is that none has been demonstrated, in independent peer-reviewed RCTs, to produce effects comparable in magnitude to injectable BoNT-A, although several show measurable, modest, instrument-detectable smoothing effects at the skin-surface level (Schagen, 2017; PMID 34957891 anti-ageing peptide review, 2021).

Mechanism of Action

The mechanistic story of Syn-Ake is best understood by separating three distinct levels: (1) the well-characterized pharmacology of native waglerin-1; (2) the design rationale by which Pentapharm reduced waglerin-1 to a synthetic dipeptide derivative; and (3) the actual evidence base for Syn-Ake's claimed activity in vivo on skin.

• Native waglerin-1 — a selective ε-subunit muscle nAChR antagonist — Waglerin-1 (Wtx-1) is a 22-residue peptide containing a single intramolecular disulfide bond, originally characterized by Weinstein, Schmidt, Bernheimer, and Smith at the U.S. Army Medical Research Institute of Infectious Diseases (Weinstein 1991, PMID 2048140; Schmidt 1992, PMID 1440639). The McArdle group at New Jersey Medical School subsequently established that waglerin-1 acts as a high-affinity competitive antagonist of the postsynaptic muscle-type nicotinic acetylcholine receptor, and uniquely discriminates between the adult (ε-subunit-containing) and neonatal (γ-subunit-containing) forms of that receptor — selectively blocking the adult form (McArdle et al., 1999; PMID 10087048).
• Mechanistic locus — α–ε subunit interface — Subsequent structure-function work (Molles et al., 2002; PMID 11724791) identified specific residues at the α and ε subunit interfaces that mediate waglerin-1's species- and subtype-selectivity, and follow-up work mapped additional ε-subunit residues that confer the α–ε interface site selectivity (PMID 12069578). The 3-D structure of waglerin-1 was characterized by NMR and circular dichroism, identifying a constrained loop conformation stabilized by the single disulfide bridge as the active pharmacophore (Sellin et al., 1996; PMID 8770182).
• Functional consequence at the neuromuscular junction — In rat extensor digitorum longus / peroneal nerve preparations, native waglerin-1 (peptide I) blocks neuromuscular transmission with a dominant postsynaptic competitive-antagonism component at the adult-type muscle nAChR (Aiken et al., 1992; PMID 1359525; Tsai et al., 1995; PMID 7638875). The result is failure of action-potential-driven endplate depolarization, leading to flaccid paralysis — the lethal mechanism in envenomed prey.
• Pentapharm design rationale — shrink to a dipeptide — Pentapharm's chemistry strategy was to identify the smallest synthetic motif retaining sufficient affinity for the muscle-type nAChR to support a cosmetic claim of "muscle-relaxing." The result was dipeptide diaminobutyroyl benzylamide diacetate — a Dab–Phe core with N-terminal benzylamide capping and acetate counter-ions. The molecule shares no obvious structural homology with waglerin-1 beyond the suggestion of mimicking a single side-chain interaction in waglerin-1's binding groove. Manufacturer literature (echoed by trade-press technical bulletins) frames this as competitive antagonism of acetylcholine binding at the muscle-type nAChR, producing "relaxation of facial mimicry muscles" and reduced expression-wrinkle formation.
• In-vitro nerve-muscle preparation data — Pentapharm's published technical dossier reports that Syn-Ake inhibited contraction of nerve-muscle preparations in vitro at micromolar concentrations, consistent with the proposed nAChR-antagonist mechanism. These data are reproduced in trade-press technical summaries but are not represented in the indexed peer-reviewed primary literature with a clear PubMed citation under "Syn-Ake" or the INCI name.
• Affinity and selectivity differences vs native waglerin-1 — The dipeptide derivative is roughly an order of magnitude smaller in molecular weight than native waglerin-1, lacks the disulfide-stabilized constrained loop, and would be expected on first-principles medicinal-chemistry grounds to bind the muscle nAChR with very substantially weaker affinity than the full-length toxin. There is no published independent biophysical comparison of Syn-Ake binding affinity for ε-containing vs γ-containing muscle nAChR analogous to the McArdle / Molles work on native waglerin-1.
• Transdermal penetration — the central problem — Even granting full intrinsic activity at the molecular target, the question that determines whether Syn-Ake can produce a meaningful clinical effect is whether sufficient peptide reaches the postsynaptic membrane of facial muscle endplates after topical application to facial skin. The stratum corneum is a profoundly effective barrier to hydrophilic peptides; the underlying epidermis, dermis, subcutis, and muscle fascia represent additional diffusion barriers; and the muscle-type nAChR is located at the postsynaptic membrane of the neuromuscular junction, deep to all of these layers. The cosmetic peptide literature broadly acknowledges this penetration problem — it is the central reason topical cosmetic peptides do not produce BoNT-magnitude effects (Schagen, 2017; Errante et al., 2020).
• Comparison vs botulinum toxin — a different molecule, target, and mechanism — BoNT-A and Syn-Ake are mechanistically unrelated. BoNT-A is a 150-kDa di-chain protein that is endocytosed into presynaptic motor neuron terminals, where its light-chain protease cleaves SNAP-25 (a core protein in the machinery that releases neurotransmitters at nerves), preventing acetylcholine vesicle fusion. The blockade is presynaptic, enzymatic, irreversible (recovery requires axonal sprouting), and produced by intramuscular injection. Syn-Ake's claimed mechanism is a small synthetic peptide acting postsynaptically at the muscle nAChR by competitive (reversible, non-enzymatic) antagonism, after topical application. The two molecules differ in size by roughly two orders of magnitude, in target by being on opposite sides of the synaptic cleft, in mechanism by being enzymatic vs competitive, and in route by being injectable vs topical. The marketing comparison ("topical Botox") is misleading at every layer.
• Antioxidant / radical-scavenging activity — A subset of cosmetic-industry studies report dose-dependent DPPH free-radical scavenging activity for the Syn-Ake molecule at typical use concentrations, suggesting an additional, mechanism-distinct contribution to overall cosmetic effect that is unrelated to the nAChR antagonism story. This is consistent with the general behavior of small peptides containing aromatic residues in DPPH assays and is unlikely to drive clinically meaningful skin effects on its own.

What the Research Shows

The molecular pharmacology of native waglerin-1 is robust, replicated, and independent — published across multiple toxinology groups in respected journals over more than three decades. The cosmetic-ingredient claims for the Pentapharm/DSM derivative rest on a much thinner foundation, dominated by manufacturer-internal in-vivo instrument-based wrinkle-depth claims that are referenced in trade-press technical bulletins and reproduced by ingredient suppliers and finished-brand marketing.

• Foundation — native waglerin-1 nAChR pharmacology — The McArdle, Molles, Sellin, Schmidt, and Weinstein papers (PMIDs 10087048, 11724791, 12069578, 8770182, 1440639, 2048140, 1359525, 7638875) establish, beyond reasonable doubt, that the 22-residue parent peptide is a competitive antagonist at the adult muscle-type nicotinic acetylcholine receptor with selectivity for the ε-subunit-containing isoform. This is the well-established scientific scaffold on which the Syn-Ake claim is built.
• Manufacturer in-vivo wrinkle-depth claim — the "52%" figure — Pentapharm's internal in-vivo test, frequently reproduced in trade and consumer summaries (e.g., the INCI Decoder ingredient profile), reports that 4% Syn-Ake solution applied for 28 days resulted in a 21% smoothing effect and a 15–20% wrinkle-depth reduction, with maximum individual values reaching ~52%. The smoothing effect was reportedly measurable on 80% of volunteers and the wrinkle-reduction effect on 73%. Critically, this is manufacturer-internal in-vivo data, not an independent peer-reviewed RCT with a clear PubMed citation. These numbers are marketing-grade evidence, not pharmacological evidence.
• In-vitro nerve-muscle inhibition — manufacturer technical dossier — Manufacturer literature reports inhibition of contraction in isolated nerve-muscle preparations at micromolar Syn-Ake concentrations, consistent with the proposed mechanism. Comparable independent replication in the standard toxinology literature is not readily identifiable on PubMed under the INCI name.
• Cosmetic peptide review literature — neutral framing — General cosmetic-peptide reviews (Lupo & Cole 2007 in Dermatologic Therapy; the related Lupo 2005 review PMID 16029675; Schagen 2017 in Cosmetics; Errante et al., 2020 Front Chem; Anti-ageing peptides and proteins for topical applications, 2021, PMID 34957891) cite Syn-Ake within the "neurotransmitter-affecting" or "biomimetic / Botox-alternative" peptide category alongside Argireline, Leuphasyl, Vialox, and SNAP-8, generally describing the mechanistic claim as nAChR antagonism while noting that independent, head-to-head RCT-grade efficacy comparisons across the class are essentially absent.
• Argireline as the most-studied class analogue — Acetyl hexapeptide-8 / Argireline (Blanes-Mira et al., 2002; PMID 18498523), the SNAP-25 N-terminal mimetic that is Syn-Ake's most prominent commercial sibling in the "Botox-alternative" peptide category, has slightly more independent literature, including small clinical pilots, but even Argireline's evidence base is widely characterized as preliminary and modest in effect size. The Argireline literature is sometimes treated as a referent for "what to expect" from this category. Subsequent reviews of acetyl hexapeptide-8 in cosmeceutical formulations have re-examined skin permeation and efficacy and reach similarly cautious conclusions about the realistic upper bound for topical neuromuscular peptide effect (Acetyl Hexapeptide-8 in Cosmeceuticals review, 2025; PMC12193160).
• Snake-venom mimetic strategy — broader context — The use of small synthetic peptides modeled on the active sites of venom-derived neurotoxins is a recognized medicinal-chemistry approach, with successful clinical examples (e.g., the synthetic conopeptide ziconotide for chronic pain). However, those successful examples typically involve injectable parenteral delivery to a target compartment that is biologically accessible from the bloodstream, not topical delivery to a deep peripheral neuromuscular junction.
• DPPH antioxidant assay activity — A cosmetic-industry-oriented study reports dose-dependent DPPH radical-scavenging activity of Syn-Ake in vitro (referenced in ingredient-database summaries). This is plausibly contributory to mild observed cosmetic effects but is not a primary mechanism.
• Tropidolaemus wagleri venomics — Independent venomic characterization of T. wagleri venom (Tan et al., 2017; PMC5327433; and the de novo venom-gland transcriptome assembly published in Toxins 2023) confirms that waglerins are the dominant neurotoxic peptides in this viper's venom and represent a convergent evolutionary innovation — the only major viperid lineage to use small nAChR-antagonist peptides as principal toxins. This contextualizes the unusualness of the parent toxin that inspired Syn-Ake.

Human Data

Human data on Syn-Ake for the cosmetic anti-wrinkle indication is restricted almost entirely to manufacturer-conducted studies. Primary scientific human data on the related native waglerin-1 toxin exists only in the form of envenomation case reports for Tropidolaemus wagleri bites, which describe local pain, swelling, and the systemic neurotoxic effects of the parent peptide, and is unrelated to the Syn-Ake cosmetic claim.

• Pentapharm in-vivo wrinkle-depth study (manufacturer dossier) — 4% Syn-Ake solution applied to crow's-feet area for 28 days produced reported 21% skin-surface smoothing and 15–20% wrinkle-depth reduction with maximum individual values reaching ~52%; smoothing measurable in 80% of volunteers, wrinkle reduction in 73%. Reproduced widely in cosmetic-industry technical bulletins and ingredient databases (e.g., INCIDecoder, ChemicalBook, supplier technical sheets). Not indexed on PubMed under "Syn-Ake" or the full INCI name; classify as manufacturer-grade evidence.
• Native waglerin-1 envenomation literature — Clinical case reports of T. wagleri bites describe primarily local effects (pain, swelling, ecchymosis) with rare systemic neurotoxicity in humans; the venom yield per bite of T. wagleri is typically lower than for clinically dangerous viperids, and serious envenomation in humans is uncommon. These case reports relate to native waglerins, not Syn-Ake, but provide indirect context for the parent toxin pharmacology in humans.
• No independent peer-reviewed RCTs of Syn-Ake — A systematic search of PubMed under "dipeptide diaminobutyroyl benzylamide diacetate," "Syn-Ake," and related terms does not return independent, blinded, placebo-controlled clinical trials with primary outcomes for this specific cosmetic peptide. This is consistent with the general pattern for the cosmetic-peptide category — most "Botox-alternative" cosmetic peptides lack independent RCT-level evidence.
• Class-level human pilot evidence (Argireline) — As the most directly comparable cosmetic peptide, Argireline has a small published clinical pilot literature including the original 30-day in-vivo evaluation in volunteers showing wrinkle-depth reduction (Blanes-Mira 2002, PMID 18498523), and a topical AH-8 pilot in blepharospasm patients receiving BoNT therapy showing extension of symptom-free interval (Beer 2012). No large independent RCT directly comparable to BoNT-A injection studies exists for Argireline either. This category-level pattern is the best available human-data benchmark for Syn-Ake.
• Cosmetic safety and irritancy testing — Standard cosmetic-ingredient safety dossier testing (HRIPT, RIPT, in-use studies) at the relevant 1–4% formula use levels has not identified meaningful sensitization, photo-irritancy, or systemic toxicity signals — consistent with the molecule's small size, low dose, topical-only route, and lack of structural alerts.
• Finished-product user studies — Some finished cosmetic brands have run their own consumer in-use panels with Syn-Ake-containing serums, with self-reported satisfaction outcomes. These are not blinded RCTs; they are marketing data.

The honest summary: there is no published peer-reviewed independent RCT proving that Syn-Ake produces meaningful wrinkle reduction in humans, only manufacturer in-vivo studies reproduced in marketing materials. The molecule is not dangerous; it is simply not robustly proven to work at the level its marketing implies.

Reconstitution & Storage

Syn-Ake is supplied to formulators either as a clear, slightly viscous aqueous solution containing ~0.05–0.1% active peptide in water/butylene glycol/glycerin, or as the dry diacetate-salt powder for custom formulation. The molecule is highly water-soluble due to its acetate counter-ions and small size, and is stable under standard cosmetic formulation conditions.

• Formulation — The maker’s documentation describes adding the solution to the water phase of an emulsion below 40 °C, at pH 5.0–7.0 (Pentapharm product documentation).

→ Calculator — vial-to-syringe math

Side Effects & Risks

Syn-Ake's safety profile is essentially what one expects from a small (~432 Da free base / ~503 Da diacetate salt) topical synthetic peptide applied at parts-per-million concentrations to intact skin: very low. Pharmacovigilance, cosmetic-ingredient safety dossier review, and decades of in-market use in finished products globally have not surfaced significant safety signals.

• Local cutaneous irritation — Uncommon. Reported by a small minority of users, typically associated with the finished product's vehicle, preservative system, fragrance, or other actives rather than with Syn-Ake itself. Manifestations are mild stinging, transient erythema, or pruritus on application; usually resolves on discontinuation.
• Contact sensitization / allergic contact dermatitis — Rare. Patch-testing data in cosmetic safety dossiers does not suggest meaningful sensitization potential at recommended use concentrations. As with any cosmetic ingredient, individual idiosyncratic sensitization is possible.
• Application-site reactions — Rare burning or itching with application near the eye margin; typically vehicle-related rather than Syn-Ake-related.
• Systemic toxicity — theoretical only — Topical application at recommended use concentrations delivers a vanishingly small absolute dose of a small, hydrophilic peptide. Even if hypothetically 100% absorbed across the entire applied skin area (an unrealistic upper bound), the resulting blood concentration would be many orders of magnitude below pharmacologically active systemic levels of native waglerin-1 in animal models. Practical systemic-toxicity risk from cosmetic Syn-Ake is essentially zero.
• Pregnancy and lactation — No specific human data. Cosmetic peptides at this molecular weight and topical route are generally not contraindicated in pregnancy by dermatology consensus, but conservative practice favors avoiding unnecessary novel actives during pregnancy.
• Pediatric use — Not indicated for cosmetic anti-aging in pediatric populations. No specific safety concern for incidental exposure.
• Drug interactions — None established. Topical Syn-Ake does not produce systemic levels relevant to drug interactions.
• BoNT comparison — no risk overlap — Syn-Ake does not share the safety risks of injectable botulinum toxin (no systemic neuromuscular weakness, no diffusion to non-target muscles, no risk of dysphagia or ptosis from inappropriate placement). Both the safety advantages and the efficacy disadvantages of being a topical peptide rather than an injected protein toxin apply.
• Snake-venom-derived stigma — Some users have psychological concerns about applying a "snake-venom peptide" to skin. The reality: Syn-Ake is a small, fully synthetic molecule designed in a lab with a structural inspiration (not derivation) from a viper-venom peptide. There is no biological snake material in any Syn-Ake-containing product.
• Interaction with active facial dermatoses — General practice for any topical cosmetic peptide, not specific to Syn-Ake, is not to apply it over open lesions, active acne, retinoid-induced peeling or irritation, or post-procedure healing skin until the skin barrier has recovered.

Bloodwork & Monitoring

Routine bloodwork or laboratory monitoring is not indicated for topical cosmetic Syn-Ake use. The molecule is a topical peptide cosmetic ingredient; systemic exposure is negligible and there are no plausible bloodwork parameters that would meaningfully reflect Syn-Ake exposure or toxicity at cosmetic use levels.

No trial, label or guideline sets monitoring for Syn-Ake, and no peer-reviewed trial of it has been published.

Commonly Stacked With

No published study has combined Syn-Ake with another cosmetic peptide. The maker’s documentation describes it as formulated alongside other actives (Pentapharm product documentation).

Stacking this? Read the receipt →

→ Calculator — vial-to-syringe math

Legal Status

Related Compounds

Neuromuscular-mimic cosmetic peptides in the same class:

Next Steps

References

1. McArdle JJ, Lentz TL, Witzemann V, Schwarz H, Weinstein SA, Schmidt JJ. Waglerin-1 selectively blocks the epsilon form of the muscle nicotinic acetylcholine receptor. J Pharmacol Exp Ther. 1999;289(1):543-550. PMID: 10087048. (The pivotal paper establishing waglerin-1's selective competitive antagonism of the adult ε-subunit-containing muscle nAChR — the molecular foundation for the Syn-Ake design rationale.)
2. Molles BE, Tsigelny I, Nguyen PD, Gao SX, Sine SM, Taylor P. Residues in the epsilon subunit of the nicotinic acetylcholine receptor interact to confer selectivity of waglerin-1 for the alpha-epsilon subunit interface site. Biochemistry. 2002;41(25):7895-7906. PMID: 12069578.
3. Molles BE, Rezai P, Kline EF, McArdle JJ, Sine SM, Taylor P. Identification of residues at the alpha and epsilon subunit interfaces mediating species selectivity of Waglerin-1 for nicotinic acetylcholine receptors. J Biol Chem. 2002;277(7):5433-5440. PMID: 11724791.
4. Sellin LC, Mattila K, Annila A, Schmidt JJ, McArdle JJ, Hyvönen M, Rauh JJ, Kuusela P. Conformational analysis of a toxic peptide from Trimeresurus wagleri which blocks the nicotinic acetylcholine receptor. Biophys J. 1996;70(1):3-13. PMID: 8770182.
5. Schmidt JJ, Weinstein SA, Smith LA. Molecular properties and structure-function relationships of lethal peptides from venom of Wagler's pit viper, Trimeresurus wagleri. Toxicon. 1992;30(9):1027-1036. PMID: 1440639.
6. Weinstein SA, Schmidt JJ, Bernheimer AW, Smith LA. Characterization and amino acid sequences of two lethal peptides isolated from venom of Wagler's pit viper, Trimeresurus wagleri. Toxicon. 1991;29(2):227-236. PMID: 2048140.
7. Aiken SP, Sellin LC, Schmidt JJ, Weinstein SA, McArdle JJ. A novel peptide toxin from Trimeresurus wagleri acts pre- and post-synaptically to block transmission at the rat neuromuscular junction. Pharmacol Toxicol. 1992;70(6 Pt 1):459-462. PMID: 1359525.
8. Tsai MC, Hsieh WH, Smith LA, Lee CY. Effects of waglerin-I on neuromuscular transmission of mouse nerve-muscle preparations. Toxicon. 1995;33(3):363-371. PMID: 7638875.
9. Tan KY, Tan NH, Tan CH. Venom proteomics and antivenom neutralization for the Chinese eastern Russell's viper, Daboia siamensis from Guangxi and Taiwan, and venomics of Tropidolaemus wagleri: deeply conserved atypical toxin arsenal. Sci Rep. 2017;7:43237. PMC5327433. (Independent venomic confirmation that waglerins are the dominant neurotoxic peptides of T. wagleri and a unique evolutionary innovation among viperids.)
10. Tang ELH, Tan NH, Fung SY, Tan CH. De Novo Assembly of Venom Gland Transcriptome of Tropidolaemus wagleri (Temple Pit Viper, Malaysia) and Insights into the Origin of Its Major Toxin, Waglerin. Toxins. 2023;15(9):585. doi:10.3390/toxins15090585.
11. Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernández-Ballester G, Ponsati B, Gutierrez L, Pérez-Payá E, Ferrer-Montiel A. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002;24(5):303-310. PMID: 18498523. (The pivotal cosmetic-peptide reference for the closest commercial analog, acetyl hexapeptide-8 / Argireline; cited as the class benchmark for "Botox-alternative" topical peptides.)
12. Lupo MP. Cosmeceutical peptides. Dermatol Surg. 2005;31(7 Pt 2):832-836. PMID: 16029675.
13. Lupo MP, Cole AL. Cosmeceutical peptides. Dermatol Ther. 2007;20(5):343-349. (Landmark cosmetic-dermatology peptide review categorizing signal, neurotransmitter-affecting, and carrier peptides; Syn-Ake falls in the neurotransmitter-affecting category alongside Argireline.). PMID: 18045359.
14. Schagen SK. Topical Peptide Treatments with Effective Anti-Aging Results. Cosmetics. 2017;4(2):16. doi:10.3390/cosmetics4020016. (Comprehensive cosmetic-peptide review describing the neurotransmitter-affecting peptide category, transdermal-penetration limitations, and the realistic upper bound of effect for topical cosmetic peptides.)
15. Errante F, Ledwoń P, Latajka R, Rovero P, Papini AM. Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy. Front Chem. 2020;8:572923. doi:10.3389/fchem.2020.572923.
16. Ferreira MS, Magalhães MC, Sousa-Lobo JM, Almeida IF. Trending Anti-Aging Peptides. Cosmetics. 2020;7(4):91. doi:10.3390/cosmetics7040091.
17. Anti-ageing peptides and proteins for topical applications: a review. Pharm Dev Technol. 2022;27(1):108-125. PMID: 34957891. (Recent comprehensive review of topical anti-aging peptides including discussion of nAChR-antagonist class members.)
18. Acetyl Hexapeptide-8 in Cosmeceuticals — A Review of Skin Permeability and Efficacy. Cosmetics. 2025; PMC12193160. (Recent review of the most-studied class analog, evaluating skin permeation barriers — directly applicable to interpreting realistic Syn-Ake efficacy ceilings.)
19. Lungu C, Considine E, Zahir S, Ponsati B, Arrastia S, Hallett M. Pilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in patients receiving botulinum toxin therapy. Eur J Neurol. 2013;20(3):515-518. PMC4747634. (The closest published controlled human pilot for any "Botox-alternative" topical peptide — context for the realistic state of evidence in this category.)
20. Public Interest in Acetyl Hexapeptide-8: Longitudinal Analysis. JMIR Dermatol. 2024;7:e54217. PMC10915729. (Recent analysis of consumer interest in the most prominent class analog; useful context for the broader marketing positioning of "Botox-in-a-jar" cosmetic peptides including Syn-Ake.)
21. PubChem Compound Summary for CID 71465152, Dipeptide diaminobutyroyl benzylamide diacetate. National Center for Biotechnology Information; 2026. (Authoritative chemistry / structure / molecular-formula reference: C23H37N5O7 for the diacetate salt.)
22. European Commission. CosIng — Cosmetic Ingredients and Substances database entry: Dipeptide Diaminobutyroyl Benzylamide Diacetate (INCI). EU Cosmetic Regulation 1223/2009; accessed April 2026.
23. Wikipedia / scholarly venomic summary: Tropidolaemus wagleri. Note: While T. wagleri's waglerin-1 selectively blocks the ε-subunit-containing acetylcholine receptor of adult muscle, there is no scientific evidence supporting the manufacturer claim that the much smaller Syn-Ake derivative achieves a comparable effect on wrinkle-producing skeletal muscle through topical application — a caveat recognized in the secondary literature.
24. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (503A categories list), versions updated April 15, April 22 and May 14, 2026. fda.gov/media/94155/download. Read October 3, 2026. (Notice that 12 peptides would leave Category 2 because their nominations were withdrawn; their removal; GHK-Cu, except injectable, back in Category 1.)

Related Research

• AHK-CuCopper Tripeptide (Hair)
• ArgirelineSNAP-25 Mimetic
• Decapeptide-12Tyrosinase Inhibitor
• GHK BasicMatrikine / Cosmetic Signaling Peptide
• FDA TrackerPCAC voted on 7 of the 12 peptides on July 23–24, 2026; FDA plans a PCAC review of the other 5 before the end of February 2027.